|Test||BCR / ABL, TRANSCRIPT p210, QUANTITATIVE POLYMERASE CHAIN REACTION (PCR)|
|Methodology||Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)|
|Description||Quantitative reverse transcription polymerase chain reaction (qRT-PCR) is the preferred assay for following documented CML patients on tyrosine kinase inhibitors. This test detects only the fusion transcripts that code for the p210 protein.
|Specimen||Draw 4mL (minimum volume 2mL) blood or bone marrow in a lavender-top (EDTA) blood collection tube. Invert several times to mix. Clotted blood is not acceptable. Transport at 2 - 8 degrees C. DO NOT FREEZE.|
|Reference Values||BCR/ABL mRNA is detected or not detected. If detected, the level is reported as a ratio of bcr/abl to abl transcripts. The detection limits of this assay in typical clinical samples ranges from .0001 to .00001 ratio of bcr/abl:abl.|
|Analytic Time||2 Days; Maximum Laboratory Time - 10 Days|
|Day(s) Test Set Up||Monday - Thursday (varies)|